Parallax Volatility Advisers
AKBA icon

Parallax Volatility Advisers’s Akebia Therapeutics AKBA Stock Holding History

Parallax Volatility Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-345,200
Closed -$249K – 2848
2022
Q1 		$249K Buy
+345,200
New +$739K ﹤0.01% 2111
2020
Q3 		– Sell
-30,000
Closed -$407K – 3015
2020
Q2 		$407K Buy
+30,000
New +$310K ﹤0.01% 2036
2016
Q2 		– Sell
-33,000
Closed -$297K – 2463
2016
Q1 		$297K Buy
+33,000
New +$268K ﹤0.01% 1627

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parallax Volatility Advisers's AKBA Position: Q3 2022 in Review

Parallax Volatility Advisers sold out of Akebia Therapeutics (AKBA) in Q3 2022, closing a stake of 109,683 shares — an estimated $39K sold.

Parallax Volatility Advisers first reported a position in AKBA in Q3 2015 and held it in 11 quarters. The position peaked at $412K in Q3 2015. 90 funds tracked by Wall St. Rank hold AKBA as of Q3 2022.

  • Parallax Volatility Advisers reported no remaining Akebia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 109,683 Akebia Therapeutics shares in Q3 2022, an estimated $39K.
  • Parallax Volatility Advisers first reported a position in Akebia Therapeutics in Q3 2015 and held it in 11 quarters.
  • Parallax Volatility Advisers's Akebia Therapeutics position peaked at $412K in Q3 2015.
  • 90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2022.

Based on Parallax Volatility Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.